Nassif, Michael E.
Windsor, Sheryl L.
Borlaug, Barry A. http://orcid.org/0000-0001-9375-0596
Kitzman, Dalane W.
Shah, Sanjiv J. http://orcid.org/0000-0002-5655-8201
Tang, Fengming
Khariton, Yevgeniy
Malik, Ali O.
Khumri, Taiyeb
Umpierrez, Guillermo
Lamba, Sumant
Sharma, Kavita
Khan, Sadiya S.
Chandra, Lokesh
Gordon, Robert A.
Ryan, John J.
Chaudhry, Sunit-Preet
Joseph, Susan M.
Chow, Chen H.
Kanwar, Manreet K.
Pursley, Michael
Siraj, Elias S.
Lewis, Gregory D.
Clemson, Barry S.
Fong, Michael http://orcid.org/0000-0002-0874-7059
Kosiborod, Mikhail N. http://orcid.org/0000-0002-3750-9789
Article History
Received: 19 August 2021
Accepted: 10 September 2021
First Online: 28 October 2021
Competing interests
: M.N.K. has received research grants from AstraZeneca and Boehringer Ingelheim and is a consultant and/or advisory board member for Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion Therapeutics, Janssen, Merck (Diabetes and Cardiovascular), Novo Nordisk, Sanofi and Vifor Pharma. M.E.N. is a consultant to Amgen and Roche Vifor and has received speaking honoraria from Abbott. B.A.B. has grant/research Support from National Institutes of Health (NIH)/NHLBI, Axon, AstraZeneca, Corvia, Medtronic, GlaxoSmithKline, Mesoblast, Novartis and Tenax Therapeutics and consulting/advisory board with Actelion, Amgen, Aria, Boehringer Ingelheim, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGMBio, ShouTi and VADovations. D.W.K. has received honoraria as a consultant for Bayer, Merck, Medtronic, Relypsa, Merck, Corvia Medical, Boehringer Ingelheim, NovoNordisk, AstraZeneca and Novartis, grant funding from Novartis, Bayer, NovoNordisk and AstraZeneca and has stock ownership in Gilead Sciences. S.J.S. has research grants from the National Institutes of Health (nos. R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis and Pfizer and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya and United Therapeutics. G.U. is partly supported by research grants from the NIH/NATS (no. UL1 TR002378) from the Clinical and Translational Science Award program, and NIH/NIDDK (no. 1P30DK111024-01) from NIH and National Center for Research Resources and has received unrestricted research support for research studies (to Emory University) from Novo Nordisk, AstraZeneca and Dexcom Inc. K.S. is an advisory board member and consultant for Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Janssen, Novartis and NovoNordisk and receives honoraria. S.S.K. receives funding from AHA (no. 19TPA34890060) and NIH (no. 1R01HL159250). S.-P.C. is a consultant for Edwards Life Sciences and has received speaking honoraria from Abbott. M.K.K. is an advisory board member for Bayer, Abiomed and CareDx. E.S.S. receives research support from, and is a consultant and speaker for, NovoNordisk, is a consultant and speaker for Boehringer Ingelheim and is a consultant and speaker for Eli Lilly. G.D.L. acknowledges research funding from NIH (nos. R01-HL 151841, R01-HL131029, R01-HL159514), American Heart Association (no. 15GPSGC-24800006) and Amgen, Cytokinetics, Applied Therapeutics, AstraZeneca and Sonivie in relation to projects that are distinct from this work; has received honoraria for advisory boards outside of the current study from Pfizer, Merck, Boehringer Ingelheim, Novartis, American Regent, Cyclerion, Cytokinetics and Amgen; and receives royalties from UpToDate for scientific content authorship related to exercise physiology. An AstraZeneca research grant to M.N.K. provided the funding for the PRESERVED-HF trial. None of the other relationships are relevant to the content of this paper. S.L.W., F.T., Y.K., A.O.M., T.K., S.L., C.H.C., L.C., J.J.R., R.A.G., M.P., S.M.J., B.S.C. and M.F. declare no competing interests.